8 results about "Alpha-synuclein" patented technology

The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease.

To provide diagnostic methods and methods for treating conditions arising from alpha-synucleopathies.MEANS FOR SOLVING THE PROBLEM: An aminopyrazole, that is, 4-[2-(4-bromophenylsulfanyl)-acetylamino]-1-phenethyl-1H-pyrazole-3-carboxylic acid or ester or amide thereof can be used to lower an amount of α-synuclein in cells of a subject for treating such conditions.SELECTED DRAWING: Figure 1

The application discloses genetically engineered ferritin against alpha synuclein, a preparation method and application thereof, and belongs to the technical field of biological medicine and protein engineering. The genetically engineered ferritin is constructed by fusing and expressing NACore polypeptide and human heavy chain ferritin through gene recombination technology, and has alpha synuclein aggregation inhibition activity. The genetically engineered ferritin can specifically combine with the NAC region of alpha synuclein, significantly inhibits the misfolding and aggregation of alpha synuclein, and provides a new drug raw material and treatment strategy for the treatment of Parkinson's disease and other alpha synuclein related neurodegenerative diseases. The genetically engineered ferritin prepared by the application has uniform particle size distribution and stable physicochemical properties. Molecular simulation verifies that the genetically engineered ferritin can efficiently combine with the NAC region of alpha synuclein. ThT fluorescence detection and CCK-8 experiments prove that the genetically engineered ferritin can inhibit the aggregation and fibrosis of alpha synuclein, and lays a solid foundation for the clinical treatment of related diseases.

The invention relates to a platelet alpha synuclein classification method, a Parkinson's disease screening kit and a Parkinson's disease screening system. According to the classification method, based on a super-resolution fluorescence imaging graph of alpha-synuclein in platelets, highlight fluorescent clusters of the alpha-synuclein are identified according to a set threshold value of a fluorescent bright cluster, and the platelets are divided into platelets with uniformly distributed alpha-synuclein according to the highlight fluorescent clusters of which the alpha-synuclein is not identified in a single platelet cell image; a highlight fluorescent cluster of at least one alpha synuclein is identified, and the highlight fluorescent cluster is divided into platelet alpha synuclein dotted distribution. The screening kit or the screening system is used for evaluating the risk of diagnosing the Parkinson's disease on the basis of comparison of the proportion of the punctiform distribution of the platelet alpha synuclein of the testee and a preset threshold value, and is beneficial to screening or diagnosis of the early Parkinson's disease.

The present invention relates to methods of identifying subjects suffering from Multiple System Atrophy (MSA) or Parkinson's Disease (PD). The method comprises subjecting a biological sample obtained from a subject to a seeded aggregation assay or a sequence of seeded aggregation assays. The invention also further provides methods of treating the identified MSA patient or the PD patient with compounds capable of inhibiting alpha synuclein aggregation.

The present invention relates to methods of treating early multiple system atrophy (MSA) or MSA-C using anti-alpha synuclein antibodies, such as Amlenetug.

Methods and kits are provided for amplifying and detecting αS proteins from samples, for example, from patients having Parkinson's Disease. For example, a method for determining a presence of a soluble, misfolded αS protein may include: contacting the sample with a monomeric, folded αS protein to form an incubation mixture; conducting an incubation cycle two or more times on the incubation mixture effective to form an amplified portion of misfolded αS protein; incubating the incubation mixture effective to cause misfolding and / or aggregation of at least a portion of the monomeric, folded αS protein in the presence of the soluble, misfolded αS protein; physically disrupting the incubation mixture effective to at least partly de-aggregate at least a portion of a misfolded αS aggregate present; and determining the presence of the soluble, misfolded αS protein in the sample by detecting at least a portion of the soluble, misfolded αS protein.

The present invention relates to a pharmaceutical composition for preventing or treating a mitochondrial-related disease comprising a Prdx3 peptide or an analog thereof as an active ingredient, and a use thereof. The pharmaceutical composition comprising a Prdx3 peptide or an analog thereof as an active ingredient can be used for the prevention and treatment of mitochondrial-related diseases by the elimination of mitochondrial autophagy, the elimination of alpha-synuclein aggregates, or the like.